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INTRODUCTION
The primary objective of hematopoietic cell transplanta-
tion (HCT) in the treatment of hematological disorders is
to eradicate the underlying disorder and replace defective
host cells with donor hematopoietic cells. Traditionally, this
objective has been achieved by myeloablative therapy before
HCT and subsequent recovery of donor hematopoiesis,
resulting in full donor chimerism. With the development of
more sensitive means to detect residual host cells, it became
possible to study the impact of mixed donor-host hemato-
poietic chimerism after HCT on outcomes such as
engraftment, graft-versus-host disease (GVHD), and disease
recurrence [1,2]. In the setting of malignant disorders, the
emergence of host hematopoietic cells after HCT was cor-
related with the delivery of less-intensive pretransplantation
conditioning therapy and with T-cell depletion of donor
grafts [3,4]. Those patients who developed mixed chimerism
beneﬁted from a decreased risk of GVHD [4-7]. Although
mixed chimerism was not universally predictive of disease
recurrence [5,8-10], abrogation of the graft-versus-leukemia
Stable Mixed Hematopoietic Chimerism After Bone
Marrow Transplantation for Sickle Cell Anemia
M.C. Walters,1 M. Patience,1 W. Leisenring,2 Z.R. Rogers,3 V.M. Aquino,3 G.R. Buchanan,3
I.A.G. Roberts,4 A.M. Yeager,5 L. Hsu,6 T. Adamkiewicz,6 J. Kurtzberg,7 E. Vichinsky,1 B. Storer,2
R. Storb,2 K.M. Sullivan7 for the Multicenter Investigation of Bone Marrow Transplantation for 
Sickle Cell Disease (see Appendix)
1Children’s Hospital Oakland, Oakland, California; 2Fred Hutchinson Cancer Research Center and the University 
of Washington, Seattle, Washington; 3University of Texas Southwestern Medical Center, Dallas, Texas; 4Royal 
Postgraduate Medical School, London, England; 5University of Pittsburgh Cancer Institute, Pittsburgh, 
Pennsylvania, 6Emory University, Atlanta, Georgia; 7Duke University Medical Center, Durham, North Carolina
Correspondence and reprint requests: Mark C. Walters, MD, Children’s Hospital Oakland, 747 52nd St, 
Oakland, CA 94609-1809 (e-mail: mwalters@mail.cho.org).
Received September 4, 2001; accepted October 8, 2001
ABSTRACT
A multicenter investigation of allogeneic bone marrow transplantation for children with sickle cell disease was con-
ducted that included 27 European and North American transplant centers. Fifty-nine patients who ranged in age
from 3.3 to 15.9 years (median, 10.1 years) received HLA-identical sibling marrow allografts between September
1991 and April 2000. Fifty-five patients survive, and 50 survive free from sickle cell disease, with a median follow-up
of 42.2 months (range, 11.8 to 115 months) after transplantation. Of the 50 patients with successful allografts, 13
developed stable mixed donor-host hematopoietic chimerism. The level of donor chimerism, measured ≥6 months
after transplantation in peripheral blood, varied between 90% and 99% in 8 patients. Five additional patients had a
lower proportion of donor cells (range, 11% to 74%). Among these 5 patients, hemoglobin levels varied between
11.2 and 14.2 g/dL (median, 11.3 g/dL; mean, 12.0 g/dL). In patients who had donors with a normal hemoglobin
genotype (Hb), the Hb S fractions were 0%, 0%, and 7%, corresponding to donor chimerism levels of 67%, 74%,
and 11%, respectively. Among patients who had donors with sickle trait, the Hb S fractions were 36% and 37%, cor-
responding to donor chimerism levels of 25% and 60%, respectively. Thus, allograft recipients with stable mixed
chimerism had Hb S levels similar to donor levels, and only 1 patient required a red blood cell transfusion beyond
90 days posttransplantation. None of the patients have experienced painful events or other clinical complications
related to sickle cell disease after transplantation. These observations strongly suggest that patients with sickle cell
disease who develop persistent mixed hematopoietic chimerism after transplantation experience a significant ame-
liorative effect.
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(GVL) activity with donor-host T-cell chimerism was
predictive of relapse in certain clinical settings (eg,
T cell–depleted transplantation for chronic myelogenous
leukemia) where the GVL effect remains an important fac-
tor for eliminating minimal residual disease [6,11,12]. Thus,
the benefits of residual host hematopoiesis and lymphoid
chimerism after HCT for malignant disorders remain some-
what uncertain.
In contrast, among those patients who undergo HCT for
nonmalignant disorders, the development of stable mixed
donor-host hematopoietic chimerism has the potential for
considerable ameliorative effect, an observation that has been
particularly well documented for β-thalassemia major and
other hereditary disorders [13-17]. The principal negative
consequence of developing mixed lymphohematopoietic
chimerism after HCT for these disorders is graft rejection,
usually accompanied by disease recurrence, typically occur-
ring in the ﬁrst year after HCT [15,18]. However, when sta-
ble hematopoietic chimerism develops after HCT, it appears
that even a minority of donor cells is sufﬁcient to overcome
an underlying genetic defect. In the example of thalassemia
major, there is an apparent enrichment of donor erythrocytes
in the blood, presumably by virtue of their improved survival
compared to their host counterparts, which are destroyed
during ineffective erythropoiesis.
Here we update and extend the observations of stable
mixed donor-host chimerism after conventional myeloabla-
tive transplantation for sickle cell anemia. In this interna-
tional, multicenter, prospective clinical investigation, we
confirm that mixed donor-host chimerism after HCT for
hemoglobin disorders has signiﬁcant therapeutic beneﬁt.
PATIENTS AND METHODS
Patients
Patients younger than 16 years who had symptomatic
sickle cell disease (SS-, SC-, or Sβ-thalassemia) and who had
HLA-identical family member donors (Hb AA or Hb AS)
were considered for marrow transplantation. All individuals
were required to meet eligibility criteria as reported earlier
[19]. Patients with extensive end-organ dysfunction were
excluded from enrollment. These conditions included
significant functional impairment (as determined by the
Lansky Play Scale or a Karnofsky score <70%), hepatic dis-
ease (active hepatitis or cirrhosis), severe renal impairment
(glomerular ﬁltration rate, <30% predicted normal for age),
severe residual functional neurologic impairment (hemiple-
gia alone was not an exclusion), or stage III-IV sickle cell
lung disease. Patients were enrolled from 27 centers in the
United States and Europe (see the “Appendix” for collabo-
rating centers). The study was approved by the institutional
review board of the Fred Hutchinson Cancer Research Cen-
ter and by institutional review boards or their equivalents at
each of the collaborating sites. All patients and/or their par-
ents or guardians gave written informed consent for their
participation.
The National Heart, Lung, and Blood Institute
appointed a data safety and monitoring board (DSMB) to
monitor patient safety and the ethical conduct and progress
of this investigation. The board consisted of 5 hematolo-
gists, a clinical statistician, and a patient advocate. The
principal investigators (M.C.W. and K.M.S.) submitted
quarterly reports to the DSMB.
Treatment Regimen
Conditioning treatment to prepare patients for trans-
plantation consisted of a combination of busulfan (BU,
14 mg/kg), cyclophosphamide (CY, 200 mg/kg), and horse
antithymocyte globulin (ATGAM, 90 mg/kg; Pharmacia
and UpJohn Co, Peapack NJ), or CAMPATH immuno-
globulin (10 mg for 5 days) in lieu of ATG [19]. Three
patients (patients 9, 10, and 11) received BU (500 mg/m2),
CY (200 mg/kg), and rabbit ATG (20 mg/kg), and another
patient (patient 6) received BU (16 mg/kg), CY (200 mg/kg),
and ATG (80 mg/kg). Since November 1994, all North
American patients had BU pharmacokinetics performed
with targeted steady-state concentrations adjusted to
400-600 ng/mL. Patients received a combination of
methotrexate and cyclosporine (CSP) for the prevention of
acute GVHD as previously reported [20,21]. CSP prophy-
laxis was given for 6 months following transplantation. Def-
inition and grading of acute and chronic GVHD have been
described [20,21].
Supportive Care
Prior to transplantation, patients not receiving chronic
transfusion therapy underwent partial exchange transfusions
to achieve fractions of Hb S that were ≤30%. All patients
who were seronegative for cytomegalovirus (CMV) received
CMV-antibody–negative screened blood products. Patients
also received prophylactic intravenous broad-spectrum
antibiotics after transplantation and oral penicillin for at
least 2 years or longer until splenic recovery was docu-
mented by liver-spleen radionuclide scans after transplanta-
tion. In response to an apparent increased incidence of
neurologic complications after transplantation [22], the fol-
lowing guidelines were employed since June 1993: anticon-
vulsant prophylaxis with phenytoin initiated with BU dosing
and continued for 6 months following transplantation (or
until CSP was discontinued); strict control of hypertension;
prompt repletion of magnesium deficiency; and mainte-
nance of hemoglobin concentrations of 9 to 11 g/dL and
platelet counts of >50,000/µL.
Analyses of Chimerism
Identiﬁcation of hematopoietic cell chimerism was made
by Y-body in situ hybridization of cells from peripheral
blood mononuclear cells when donor and recipient were
sex-mismatched. When donor-host pairs were not sex mis-
matched, chimerism analysis was performed by Southern
blotting of variable-number tandem repeats (VNTR) in
peripheral blood genomic DNA using the YNH, M27β, or
TBQ probes, by restriction fragment length polymorphism
(RFLP), or by microsatellite analysis. To assess the relative
contributions of donor and recipient, these assays were
quantitated by densitometry of autoradiographs for VNTR
and RFLP analyses. Assay sensitivities to 5% for these tech-
niques were confirmed by mixing experiments of known
amounts of patient and donor cells or DNA. These analyses
were performed at day 84 and at 6 months following
transplantation, and biannually thereafter if evidence of
mixed chimerism was present. Microsatellite analyses were
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performed using standard techniques [23,24]. These studies
were performed in parallel with evaluations of hemoglobin
levels and Hb S fraction quantiﬁcation by electrophoresis.
Late Effects Evaluation
Cerebral magnetic resonance imaging (MRI) and
angiography (MRA) examinations were requested for all
patients before, and 1 and 2 years after, transplantation.
Similarly, pulmonary function tests (total lung capacity,
forced vital capacity [FVC], residual volume, and the ratio
of forced expiratory volume to FVC) were measured before
and at annual intervals after transplantation.
Pulmonary function testing was based on common
methods for comparison of reference values [25]. Actual
lung volumes were compared to predicted values from age-
and sex-matched control subjects to generate a percentage
of the predicted value for each subject. The staging criteria
for sickle cell pulmonary disease described by Powars et al.
was used for grading restrictive pulmonary disease [26].
Mild restrictive pulmonary disease was defined as 80% of
predicted normal or 1 standard deviation (SD) below nor-
mal; moderate was deﬁned as 60% of predicted normal, or
2 SDs below normal; and severe was deﬁned as 40% of pre-
dicted normal, or 3 SDs below normal.
Statistical Analysis
Statistical analyses were performed to summarize results.
The method of Kaplan and Meier was used to estimate sur-
vival and event-free survival (where an event was deﬁned as
death, graft rejection, or return of sickle cell disease) [27]. A
cumulative-incidence curve for graft rejection was also calcu-
lated [28]. Event-free survival was deﬁned as survival in the
absence of clinical vaso-occlusive complications typical of
sickle cell disease. Stable mixed chimerism was deﬁned as 5%
to 95% donor chimerism, as determined by standard molec-
ular techniques, 6 months or longer after transplantation.
Hazard ratios were estimated from proportional hazards
regression models. Death without rejection was treated as a
competing-risk event, and patients were censored at the
time of death. All P values were 2-sided and were based on
likelihood-ratio statistics.
RESULTS
Fifty-nine children with sickle cell anemia, sickle β+-
thalassemia, or sickle-OArab received HLA-identical sibling mar-
row allografts between September 1991 and April 2000. Of
these patients, 50 survive free of disease with a median follow-
up of 42.2 months (range, 11.8 to 115 months). Five patients
had graft rejection followed by return of sickle cell disease a
median of 5.1 months (range, 2.1 to 8.9 months) after HCT
(Table 3), and 4 patients died of intracranial hemorrhage (n = 1)
or GVHD (n = 3). The Kaplan-Meier probabilities of survival
and event-free survival were 93% and 84%, respectively (Fig-
ure 1). The cumulative incidence of recurrent sickle cell dis-
ease was 9%. Among the 50 patients surviving free of sickle
cell disease, all but 1 had chimerism studies performed after
HCT. Of these, 13 patients (9 male, 4 female) had stable
mixed donor-host hematopoietic chimerism detected after
HCT. For this analysis, patients with stable mixed chimerism
were divided into 2 groups. Group 1 consisted of patients with
90% or greater donor chimerism (n = 8), and group 2 had
patients with <75% donor cells after HCT (n = 5).
Characteristics of Patients With Mixed Chimerism
Thirteen patients with stable mixed chimerism ranged in
age from 4.2 to 13 years (median, 6.9 years). The indications
for transplantation are shown in Tables 1 and 2. Seven
Figure 1. Outcome after transplantation for 59 children with
advanced symptomatic sickle cell disease. Kaplan-Meier estimates for
survival and event-free survival following marrow transplantation are
shown. An event is deﬁned as death, graft rejection, or recurrence of
sickle cell disease. A cumulative incidence curve for graft rejection and
return of sickle cell disease is also depicted.
Table 1. Characteristics of Patients Who Developed Stable Mixed Chimerism With ≥90% Donor Chimerism*
Age at Indication Donor Hb Time After Percentage Donor
Patient BMT, y for BMT Genotype BMT, mo Chimerism, % Hb S, %
22 6.9 Recurrent VOC AA 48.2 90-95 —
42 7 Stroke AS 12.2 95-99 40
43 4 CNS disease AS 7.8 90 34
44 12 Recurrent ACS AS 14.3 95 41
45 9 Recurrent ACS AS 13 90-95 38
46 4 Recurrent ACS AA 9 93 0
50 7.6 Stroke AS 12.3 90 37
55 6 Stroke AS 17 90 38
*VOC indicates vaso-occlusive crises; AA, healthy donor; AS, sickle cell–trait donor; ACS, acute chest syndrome.
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patients had a stroke or other signiﬁcant central nervous sys-
tem (CNS) disease before HCT, 5 had recurrent episodes of
acute chest syndrome, and 1 had recurrent vaso-occlusive
painful crises. Thus, the distribution of eligibility criteria
among those with stable mixed chimerism did not differ
significantly from the larger group of 59 patients. Donor
hemoglobin genotype is shown, and 7 patients had donors
with sickle cell trait. Six patients had received more than
10 red blood cell (RBC) transfusion exposures before HCT,
5 received fewer than 10, and, in 2 patients, the transfusion
exposure before HCT was not known. Serum ferritin levels
varied between 58 and 5066 ng/mL (median, 830 ng/mL).
Three patients had evidence of alloimmunization to RBC
antigens before HCT. Platelet antibody screening was per-
formed in 8 patients before HCT, and results were negative
in each patient tested. Eight of 13 patients had busulfan
pharmacokinetics tests performed to ensure average steady-
state levels of 400 to 600 ng/mL in the blood. Three of
5 patients in group 2 had steady-state levels of 413, 450, and
619 ng/mL; in 2 patients, pharmacokinetics studies were not
performed. There was no major ABO blood type incompati-
bility among group 2 donor-host pairs. ABO incompatibility
was found in 1 pair among 8 group 1 patients. All patients
received bone marrow allografts with a median cell dose (of
total nucleated cells [TNC]) of 3.0 × 108/kg recipient weight
(range, 0.82-5 × 108/kg recipient weight). The median doses
of TNC infused among group 1 and group 2 patients who
developed stable mixed chimerism were 2.4 × 108/kg and
3.1 × 108/kg, respectively.
Impact of Mixed Chimerism on Outcome
Overall, 11 of 59 patients (19%) developed acute or
chronic GVHD, which was the cause of death in 3 patients.
In contrast, none of 13 patients with stable mixed chimerism
experienced acute or chronic GVHD (P = .05). There was no
apparent association between the development of mixed
chimerism and graft rejection/disease recurrence. This
observation contrasts with observations after transplantation
for cases of β-thalassemia major, in which mixed chimerism
was associated with an increased risk of disease recurrence
[14]. Other factors evaluated for their association with devel-
oping stable mixed chimerism and rejection after transplan-
tation for sickle cell disease included patient age, patient sex,
donor sex, donor hemoglobin genotype, the number of
transfusions received, incidence of RBC alloimmunization,
and the presence or absence of chelation therapy. A propor-
tional hazards regression analysis was performed to deter-
mine if any of these factors was associated with recurrent
disease or with developing stable mixed chimerism, and the
results are presented in Tables 3 and 4, respectively.
Although most factors failed to achieve statistical signifi-
cance, in part because of the infrequency of these events,
there was a trend suggesting that patients receiving chelation
therapy for transfusional iron overload had an increased risk
of recurrent sickle cell disease (P = .04). Of interest, neither
RBC transfusion exposures or iron chelation therapy was
associated with developing stable mixed chimerism after
transplantation. However, patients younger than 10 years
were signiﬁcantly more likely to develop mixed chimerism
than those who were older than 10 years (P = .001) (Table 4).
To determine the impact of stable mixed chimerism on
sickle cell disease expression, group 2 patients were moni-
tored for hematological and clinical manifestations of the
underlying disease (Table 2). These 5 patients had stable
mixed chimerism with a follow-up period that ranged from
22 to 70.2 months (median, 36.3 months) after HCT, when
last evaluated. Hemoglobin levels varied from 11.2 to
14.2 g/dL (median, 11.3 g/dL). Only patient 38 required a
Table 2. Characteristics of Patients Who Developed Stable Mixed Chimerism With <75% Donor Chimerism
Age at Indication Donor Hb Time After Percentage Donor Hemoglobin
Patient BMT, y for BMT Genotype BMT, mo Chimerism, % Concentration, g/dL Hb S, % Retic, %*
13 5.2 Stroke AA 64 11 11.3 7 7.8†
18 8.2 Recurrent ACS AA 70 67 14.2 0 1.0
38 5.4 Stroke AS 36 20-30 11.8 36 1.9
49 5 Stroke AA 29 74 11.3 0 —
52 5 Recurrent ACS AS 22 60 11.2 37 1.5
*Retic indicates reticulocyte production index.
†Uncorrected reticulocyte count.
Table 3. Univariate Analysis of Risks for Graft Rejection/Recurrent Disease
After Transplantation for Sickle Cell Disease*
No. of Patients With
Risk Factor Graft Rejections OR (95% CI) P
Age at transplantation
<10 y (n = 29) 2 1.0
≥10 y (n = 30) 3 1.4 (0.2-8.4)
.71
Patient sex
Female (n = 23) 3 1.0
Male (n = 36) 2 0.5 (0.1-2.7)
.38
Donor sex
Female (n = 29) 4 1.0
Male (n = 25) 1 0.3 (0.0-2.3)
.18
Donor genotype
AS (n = 35) 3 1.0
AA (n = 23) 2 0.9 (0.2-5.6)
.94
RBC alloimmunization
No (n = 40) 3 1.0
Yes (n = 16) 2 1.8 (0.3-11)
.53
Chelation therapy
No (n = 36) 1 1.0
Yes (n = 21) 4 7.3 (0.8-65)
.04
Pre-BMT ferritin levels, ng/mL
<2000 (n = 43) 3 1.0
≥2000 (n = 12) 1 1.1 (0.1-11)
.93
*OR indicates odds ratio; CI, conﬁdence interval.
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RBC transfusion more than 90 days post-HCT, and this
patient currently remains independent of RBC transfusions.
Reticulocyte fractions were elevated in 2 patients who had
the lowest levels of donor chimerism (Table 2, patients 13
and 38). The Hb S fractions, depicted serially in Figures 1
and 2, demonstrated that Hb S fractions closely matched
donor Hb S levels, even when there was a minority of donor
cells. Together, these data strongly suggest that there was an
enrichment of donor RBCs due to their longer life span.
Clinically, among all group 1 and 2 patients, there were
no painful vaso-occlusive crises after HCT, and no patients
experienced other sickle cell–related clinical complications.
There were no significant differences in hematological or
clinical observations when recipients who had sickle cell
trait and donors of normal hemoglobin were compared.
Group 2 patients were also monitored for effect of HCT
on pulmonary function and on cerebral imaging by MRI as
previously reported (Table 5). These evaluations showed sta-
bilization of abnormalities that were present before HCT. As
previously reported, patient 18, who had been studied by
cerebral MRI 3 months before transplantation, developed
new MRI lesions 1 month after transplantation, but subse-
quent annual studies have remained stable. It is likely that
this patient had progression of CNS disease before trans-
plantation. All 13 group 1 and 2 patients with stable mixed
donor host chimerism were screened for quality of life, and
all have Karnofsky or Lansky Play scale scores of 100%.
Thus, together, these data demonstrate that patients who
develop stable mixed chimerism after HCT experience clini-
cal and subclinical cessation of sickle cell–related events with
excellent quality of life and no chronic GVHD.
DISCUSSION
This report updates observations of stable mixed donor-
host hematopoietic chimerism that developed after conven-
tional myeloablative HCT for children with symptomatic
sickle cell disease. These observations mirror similar phe-
nomena after allografting for β-thalassemia major, in which
up to 10% of patients had residual host cells that persisted
for longer than 2 years after HCT [13,14,17,29]. These
results are also similar to observations by European centers
after conventional HCT for sickle cell disease, where 12 of
103 patients developed stable mixed chimerism [30-33].
Although our results are not entirely novel, a systematic
evaluation of the outcome of stable mixed chimerism in
sickle cell disease has not previously been performed, and
thus these observations provide a rational basis for consider-
ing nonmyeloablative HCT for hemoglobinopathies. In
both hemoglobin disorders, there were no apparent delete-
rious effects of residual erythropoiesis by defective host
cells, an outcome consistent with the idea that replacement
by full donor chimerism is not a requirement for signiﬁcant
amelioration, if not cure, of these disorders. Although a
longer period of follow-up will be required to assess the
long-term impact of mixed chimerism on the clinical and
subclinical expression of sickle cell disease, it is possible that,
similar to chronic RBC transfusions, mixed chimerism will
significantly reduce but not altogether eliminate adverse
clinical events such as stroke [34,35]. Alternatively, the expe-
rience of mixed chimerism after transplantation for leukocyte-
adhesion defect [16], selected metabolic storage disorders
[36], immunodeﬁciency syndromes [37], and chronic granu-
lomatous disease [38-40] supports the idea that low-level
(15% to 30%) donor chimerism is sufﬁcient for a signiﬁcant
beneﬁcial effect in these hereditary disorders. It is likely that
among those who have very low-level donor chimerism after
transplantation for sickle cell anemia, the clinical benefit
will hinge on the extent to which circulating sickle erythro-
cytes are reduced or eliminated [41]. However, in our small
cohort, we found no evidence that those with a minority of
donor cells experienced exacerbation of their disease, in
contrast to observations of chimerism after transplantation
in a murine model of sickle cell anemia [42].
The natural enrichment of donor erythrocytes is per-
haps not very surprising in β-thalassemia major, a hemoglo-
bin disorder in which anemia is largely the consequence of
ineffective erythropoiesis [43]. In this setting, normal ery-
throid precursors should have a survival advantage over tha-
lassemic counterparts in the marrow and thus generate a
majority of donor erythrocytes in the blood. In sickle cell
anemia, however, peripheral hemolysis is a key determinant
of anemia. Nonetheless, here too we observed a survival
advantage of donor erythrocytes, and even a small fraction
of donor cells eliminated clinical and subclinical evidence of
vaso-occlusion, although some patients had a persistent mild
anemia. Previously, we reported overrepresentation of
donor erythroid progenitors in the marrow compared to
donor myeloid counterparts in a patient who evolved to
develop graft rejection [44], observations that were recapitu-
lated in patients who developed mixed chimerism after non-
myeloablative preparation for transplantation [45]. Together,
these observations suggest that donor erythroid progenitors
have a survival advantage over sickle counterparts in the
marrow. Thus, efforts to repopulate hemoglobinopathy
Table 4. Univariate Analysis of Risks for Developing Stable Mixed
Chimerism (MC) After Transplantation for Sickle Cell Disease
No. of Patients
Risk Factor With Stable MC* OR (95% CI) P
Age at transplantation
<10 y (n = 28) 12 1.0
≥10 y (n = 29) 2 0.1 (0.02-0.5)
.001
Patient sex
Female (n = 22) 5 1.0
Male (n = 35) 9 1.2 (0.3-4.1)
.80
Donor sex
Female (n = 28) 7 1.0
Male (n = 25) 7 1.2 (0.3-4.0)
.80
Donor genotype
AS (n = 33) 8 1.0
AA (n = 23) 6 1.1 (0.3-3.8)
.88
RBC alloimmunization
No (n = 40) 9 1.0
Yes (n = 14) 4 1.4 (0.4-5.5)
.65
Chelation therapy
No (n = 35) 10 1.0
Yes (n = 20) 3 0.4 (0.1-1.8)
.24
Pre-BMT ferritin levels, ng/mL
<2000 (n = 41) 11 1.0
≥2000 (n = 12) 3 0.9 (0.2-4.0)
.90
*One rejecting patient also had MC >6 months after transplantation.
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recipients with normal erythrocytes that have a natural sur-
vival advantage in the marrow and in circulation might hold
the key to success in curing these disorders. The source of
these cells might be autologous hematopoietic stem cells
transduced by a replacement gene vector that is able to pro-
duce stable levels of a developmentally regulated β-globin
gene over repetitive cell cycles, at a balanced level in rela-
tion to the complementary α-globin chain [44]. Given the
complexities of accomplishing this aim, a more expedient
alternative might be to use HLA-compatible donors after
preparation for transplantation with nonmyeloablative but
immunosuppressive therapy to establish stable hemato-
poietic chimerism [46,47]. Here the principal challenge is to
overcome immunological barriers to donor-host tolerance,
barriers that were overcome serendipitously after conven-
tional myeloablative conditioning in the cohort we
described here. To explore this challenge, we have initiated a
multicenter collaborative investigation of nonmyeloablative
preparation before allogeneic marrow transplantation for
symptomatic sickle cell disease.
The possibility of inducing stable mixed hematopoietic
donor-host chimerism presents several potential advantages
over treatment with conventional conditioning regimens.
First, by using less toxic conditioning regimens, the resultant
tissue injury caused by cytoreductive therapy might be miti-
gated. In addition, it is possible that conditions conducive to
cytokine secretion and host peptide fragment presentation
that are postulated to promote GVH reactions might be
decreased as a result of eliminating the administration of
high-dose chemotherapy and radiation before HCT [48-50].
Finally, a steady source of host lymphocytes and antigen-
presenting cells (APC) that survive nonmyeloablative condi-
tioning might promote donor-host tolerance by negative
selection of alloreactive donor T cells in the thymus and
peripheral locations [51]. Thus, the risk of GVHD in those
patients who develop stable chimerism might be reduced or
even eliminated after HCT using cells from HLA-identical
sibling donors. Concerns that concurrent major histocom-
patibility complex restriction by host thymocytes and by
donor APC might actually induce a state of immunodefi-
ciency have not been realized. In fact, immune reconstitution
appears accelerated among those who develop stable
chimerism [52,53]. In animals that developed stable mixed
chimerism, immune-competent grafts were established that
supported donor-specific tolerance, as indicated by the
acceptance of donor skin and organ grafts [54,55].
Figure 2. Serial determinations of donor chimerism and Hb S fractions after transplantation. A, The fraction of donor cells in the blood ( ) and
Hb S fraction () are depicted at regular intervals after transplantation with a follow-up period extending to more than 5 years after transplantation.
The relationship between donor chimerism and the Hb S fraction is shown. Patients 13, 18, and 49 who had Hb AA donors are shown. B, Hb S and
chimerism studies from patients 38 and 52 who had Hb AS donors are shown.
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Thus, nonmyeloablative regimens aimed at inducing
mixed chimerism are particularly attractive in the setting of
hereditary anemias such as sickle cell anemia, where the
chief concerns of extending the option of stem cell trans-
plantation to all patients are the risks of adverse events asso-
ciated with conventional cytoreductive therapy and GVHD.
Logically, older patients who have experienced chronic
vaso-occlusive organ damage that excludes them from
conventional allogeneic transplantation might make ideal
candidates for an initial clinical trial. However, transfusion
exposures that increase the risk of graft rejection [56] and
GVHD in older recipients should prompt caution until a
preparative regimen to control HVG and GVH reactions in
these individuals has been deﬁned. The results of this study
support the notion that younger patients might be more
likely than adults to develop stable mixed chimerism after
transplantation. First, we found that graft rejection after
conventional transplantation was associated with iron chela-
tion therapy. It is possible that chelation therapy is a surro-
gate for exposures to minor histocompatibility antigens
expressed on leukocytes in RBC products, which generated
alloreactive immune responses responsible for graft rejec-
tion. Thus, younger patients with fewer transfusion expo-
sures before transplantation might experience a lower
probability of disease recurrence after nonmyeloablative
preparation. Second, we observed an association between
younger age and having stable mixed chimerism after con-
ventional transplantation. Thus, it is possible that preserved
thymic activity in these younger patients was a determinant
that promoted bidirectional donor-host tolerance. In partic-
ular, a lower rate of GVHD in children is very likely to con-
tribute to a better outcome, a prediction supported in part
by recent observations after nonmyeloablative transplanta-
tion in 2 adult patients with sickle cell disease [57]. Still,
given the attendant risk of graft rejection that is very likely
to follow nonmyeloablative preparation, it will be important
to study this approach in the setting of a well-controlled
multicenter clinical investigation by centers experienced in
allogeneic transplantation. If successful, however, this novel
therapy would dramatically alter the approach to transplan-
tation for hereditary anemias like sickle cell disease and
extend its availability.
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APPENDIX
The following investigators and centers participated
in this collaborative study: Ann Arbor, MI (J. Levine, Uni-
versity of Michigan); Atlanta, GA (J.R. Eckman, L. Hsu, T.
Adamkiewicz, A. Yeager, Emory University); Birmingham,
UK (P.J. Darbyshire); Boston, MA (E. Guinan, O. Platt, Dana
Farber Cancer Institute and The Children’s Hospital, Har-
vard University; L. McMahon, Boston Comprehensive
Sickle Cell Center); Bronx, NY (L. Benjamin, R. Nagel,
Montefiore Medical Center, Albert Einstein College of
Medicine); Brooklyn, NY (L. Guarini, Interfaith Medical Cen-
ter; K. Viswanathan, Brookdale Hospital; Rita Bellevue, NY
Methodist Hospital); Chapel Hill, NC (R. Redding-Lallinger,
Table 5. Follow-up Studies of Cerebral Imaging and Pulmonary Function Among Group 2 Patients With Stable Mixed Donor-Host Chimerism*
Patient Indication Baseline 1 Year 3 and ≥4 Years
No. for BMT Cerebral MRI Post-BMT Post-BMT
13 Stroke Multiple periventricular Stable
and R. frontal foci of 
increased T2 signal
18 ACS Leukomalacia New R. frontal-parietal Stable/stable
infarct
38 Stroke R. MCA infarction/R. Stable 
brainstem abnormality
49 Stroke L. frontal and bilateral corona Stable 
radiata and centrum 
semiovale abnormalities
52 Recurrent ACS Bilateral fronto-parietal foci Stable
with high signal
Patient Indication Baseline 1 Year 2 Years 3 Years ≥4 Years
No. for BMT PFT Results Post-BMT Post-BMT Post-BMT Post-BMT
13 Stroke Normal
18 ACS, abnormal MRI Mild RPD Mild RPD Mild RPD Mild to moderate Mild RPD
38 Stroke Moderate RPD Moderate RPD RPD
49 Stroke Not studied (too young)
52 Recurrent ACS Normal Normal
*R. indicates right; MCA, middle carotid artery; L., left; PFT, pulmonary function test; RPD, restrictive pulmonary disease.
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E. Orringer, J. Wiliey, University of North Carolina); Cleve-
land, OH (M. Nieder, Rainbow Babies Hospital, Case West-
ern Reserve University); Creteil, France (F. Bernaudin, G.
Souillet, Hopital Henri Mondor); Dallas, TX (G.R.
Buchanan, Z.R. Rogers, V Aquino, University of Texas
Southwestern Medical Center at Dallas); Denver, CO (R.
Giller, P.A. Lane, University of Colorado); Detroit, MI (I.
Sarnaik, P. Swerdlow, Wayne State University); Durham, NC
(M. Telen, T. Kinney, J. Kurtzberg, K.M. Sullivan, Duke
University Medical Center); Fort Worth, TX (G. Eames, D.
Friedman); Gainesville, FL (A. Kedar, J. Wingard, University
of Florida); Houston, TX (K.W. Chan, University of Texas,
M.D. Anderson); London, UK (S.C. Davies, I. Dokal, I.
Roberts, Royal Postgraduate Medical School); Los Angeles,
CA (R. Parkman, D. Powars, N. Kapoor, Wing-Yen Wong,
T. Coates, University of Southern California; Alexis
Thompson, Stephen Feig, University of California at Los
Angeles); Miami, FL (A.S. Wayne, T. Harrington, C.
Pegelow, University of Miami); Milwaukee, WI (B. Camitta,
D. Margolis, J.P. Scott, Medical College of Wisconsin);
Minneapolis, MN (P. Orchard, S. Nelson, L. Krishnamurti, J.
Wagner, University of Minnesota); New Haven, CT (B.
Sleight, J. Rappeport, Yale University); Montreal, Quebec (H.
Hume, Hopital Ste-Justine); New Orleans, LA (L. Yu, R.
Veith, Louisana State University; C. Scher, Tulane Medical
Center); New York, NY (F. Blei, NYU Medical Center; J.
Lipton, Mt. Sinai Medical Center; D. Wethers, St. Luke’s
Roosevelt Hospital; S. Piomelli, Columbia University); Oak-
land, CA (L. Styles, E. Vichinsky, M. Walters, Children’s
Hospital Oakland); Philadelphia, PA (K. Ohene-Frempong,
K. Smith-Whitley, N. Bunin, University of Pennsylvania);
Saint Louis, MO (D. Wall, A. Chu, St. Louis University; S.
Shenoy, R. Hayashi, Washington University); Rochester, NY
(J. Horan, R. Duerst, University of Rochester); Saint Peters-
burg, FL (M. Klemperer, University of S. Florida); Sao Paolo,
Brazil (C. Bonfim, Federal University of Parana; S. Bran-
dalise, R. Pasquini, University of Campinas); San Francisco,
CA (W.C. Mentzer, M. Cowan, University of California,
San Francisco); St. Augustin, Germany (R. Dickerhoff, T.
Klingebiel, University of Bonn); Seattle, WA (R. Storb, A.
Woolfrey, J.E. Sanders, Fred Hutchinson Cancer Research
Center and the University of Washington); Stanford, CA (M.
Amylon, B. Glader, Stanford University); Tucson, AZ (M.L.
Graham, University of Arizona); and Washington, DC (P.
Dinndorf, E. Bayever, O. Castro, Children’s Hospital
National Medical Center, George Washington University
and Howard University).
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